NAPLEX Flashcards: Adverse Drug Event Reporting

What this deck covers

This deck focuses on Adverse Drug Event Reporting, giving you a quick way to review the definitions, rules, and examples that matter most for NAPLEX.

How to use these flashcards

Work through these flashcards in short sessions. Try to answer each prompt before flipping the card, then revisit any cards you miss until the explanation feels automatic.

Flashcard 1: Which option is the best reason to report a suspected adverse event even if causality is uncertain?

Answer: To support signal detection; suspected association is sufficient for reporting. Reporting suspicions aids in pharmacovigilance by contributing to data aggregation for detecting potential safety signals.

Flashcard 2: What key product details should be included to strengthen an adverse event report for a drug product?

Answer: Drug name, strength, dose, route, lot number if known, and therapy dates. These details provide precise product identification and usage context, enhancing the report's value for causality assessment.

Flashcard 3: Identify the correct action when an ADE suggests a medication error with ongoing patient harm.

Answer: Ensure patient safety first, then document and report via institutional process and FDA if needed. Prioritizing patient safety addresses immediate risks, followed by documentation and reporting to prevent recurrence and ensure compliance.

Flashcard 4: Which causality tool is commonly used to assess the likelihood that a drug caused an ADR?

Answer: Naranjo algorithm. The Naranjo algorithm uses a scoring system based on temporal association and other factors to estimate causality probability.

Flashcard 5: Which term describes a preventable event that may cause inappropriate medication use or harm?

Answer: Medication error. This term focuses on preventable failures in the medication use process that could lead to patient harm if not intercepted.

Flashcard 6: What is the minimum event information element needed for a valid individual case safety report?

Answer: An adverse event or outcome description. Describing the adverse event fulfills ICH minimum criteria by providing the foundational details for safety evaluation.

Flashcard 7: Which reporting program is used for adverse events involving dietary supplements and other FDA-regulated products?

Answer: MedWatch. MedWatch provides a centralized system for reporting issues with dietary supplements to support FDA regulatory oversight.

Flashcard 8: Which FDA reporting pathway is used for adverse events related to vaccines?

Answer: VAERS (Vaccine Adverse Event Reporting System). VAERS, co-managed by FDA and CDC, specifically monitors vaccine safety to identify rare or unexpected adverse events.

Flashcard 9: What is the minimum reporter information element needed for a valid individual case safety report?

Answer: An identifiable reporter. Reporter identifiability allows for necessary follow-up inquiries to clarify or expand on the reported safety information.

Flashcard 10: Which reporting program is used for adverse events or product problems with medical devices?

Answer: MedWatch (including Medical Device Reporting pathways). MedWatch integrates device reporting pathways to ensure systematic surveillance of medical device safety and performance.

Flashcard 11: Which MedWatch form number is used for mandatory reporting by manufacturers, packers, and distributors?

Answer: FDA Form 3500A. Form 3500A is required for industry to comply with FDA regulations on reporting serious events and product issues.

Flashcard 12: What is the minimum product information element needed for a valid individual case safety report?

Answer: A suspect product (drug, biologic, device, or vaccine). Identifying a suspect product is essential per ICH guidelines to link the event to a specific FDA-regulated item for analysis.

Flashcard 13: What is the key distinction between an ADE and an ADR?

Answer: ADE includes harm from errors; ADR is nonpreventable at normal doses. ADEs encompass both preventable and nonpreventable harms, while ADRs are limited to inherent drug risks at normal doses.

Flashcard 14: Identify what should be done if a patient report lacks one minimum element for a valid safety report.

Answer: Obtain missing minimum element; if unobtainable, report with available information and note gaps. Attempting to complete minimum criteria ensures report validity, while noting gaps allows partial data to contribute to surveillance.

Flashcard 15: What is the FDA definition of a serious adverse event for reporting purposes?

Answer: Death, life-threatening event, hospitalization, disability, anomaly, or intervention needed. FDA criteria for seriousness prioritize events with significant health impacts to expedite review and potential interventions.

Flashcard 16: Which ADR type is dose-related and predictable from known pharmacology (Type A vs Type B)?

Answer: Type A (augmented). Type A reactions arise from exaggerated normal pharmacological actions, making them predictable and often avoidable by dose adjustment.

Flashcard 17: Which option best defines a life-threatening adverse event in FDA serious event criteria?

Answer: Patient was at immediate risk of death at the time of the event. This criterion emphasizes the immediacy of mortal risk during the event to classify it as requiring urgent reporting.

Flashcard 18: What is the definition of an adverse drug reaction (ADR) per standard pharmacovigilance use?

Answer: Noxious, unintended response at normal doses for prophylaxis, diagnosis, or therapy. The WHO pharmacovigilance definition emphasizes harm occurring at standard therapeutic doses to distinguish from errors or overdoses.

Flashcard 19: What key clinical details should be included to strengthen an adverse event report for patient assessment?

Answer: Timeline, labs/vitals, comorbidities, concomitant meds, and outcome. Including these elements offers a comprehensive patient context, facilitating thorough evaluation of the event's causality and impact.

Flashcard 20: Which MedWatch form number is used for voluntary reporting by health professionals and consumers?

Answer: FDA Form 3500. Form 3500 supports voluntary submissions to encourage widespread participation in pharmacovigilance without regulatory mandates.

Flashcard 21: What is the FDA meaning of an unexpected adverse event in postmarketing safety reporting?

Answer: Not listed in the current labeling or not consistent with known specificity or severity. Unexpected events deviate from labeled information, prompting further investigation in postmarketing surveillance.

Flashcard 22: What is the definition of an adverse drug event (ADE) in clinical practice?

Answer: Any injury from medication use, including errors, ADRs, and overdoses. This broad definition captures all medication-related harms to facilitate comprehensive safety monitoring in healthcare settings.

Flashcard 23: Which FDA program is used by health professionals to report serious adverse events and product problems?

Answer: MedWatch (FDA Safety Information and Adverse Event Reporting Program). MedWatch enables voluntary reporting by professionals to detect post-marketing safety signals for drugs and other products.

Flashcard 24: Which ADR type is non-dose-related, unpredictable, and often immunologic or idiosyncratic?

Answer: Type B (bizarre). Type B reactions involve mechanisms unrelated to dose, such as hypersensitivity, rendering them unpredictable and rare.

Flashcard 25: What is the minimum patient information element needed for a valid individual case safety report?

Answer: An identifiable patient. Patient identifiability is a core ICH requirement to ensure report traceability and prevent duplicate entries in databases.